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SHORT COMMUNICATION
Treatment with para-chlorophenylalanne antagonises the emetic response
and the serotonin-releasing actions of cisplatin in cancer patients
AB Alfieri and LX Cubeddu
Department ofPharmacology, School ofPharmacy, Central University of Venezuela.
S_q To test the role of serotonin in chemotherapy-induce nausea and emesis, ten cancer patets were
pretreated with the seroton synthesis inhibitor para-chlorophenylalanine (PCPA). PCPA (2 g 8 hourly for 2
or 3 days pnror to cslatin) d the spontaneous urinary excretion of 5-hydroxyindoleacetic acid
(5-HIAA), inhibited the incease in urinary 5-HIAA indud by dsplatin and markedly attenuated the acute
period of nausea and vomiting t ed with the cytotoxic drug. These results indicate that gastrointestinal
serotonin mediates iplatin-duced emeas and that the amount of serotoni relased by csplatm is a major
factor in dmining the severity of the acute period of emesis experieced by the patiet
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Cancer chemotherapeutic drugs are known to induce nausea
and emesis as side-effects (Gralla, 1983; Martin 1992). The
ability of 5-HT3 receptor antagonists to inhibit chemo-
therapy-induced emesis (Costal et al., 1986; Miner and
Sanger, 1986; Cubeddu et al., 1990) and the observation that
emesis due to chemotherapeutic drugs is associated with the
relase gastrointestinal serotonin (Cubeddu et al., 1990, 1992;
Cubeddu and Hoffmann, 1994) suggests that serotonin plays
a key role in mediating emesis induced by cancer chemo-
therapy. In ferrets, depletion of tissue serotonin reduced
cisplatin and whole-body radiation-induced emesis (Bares et
al., 1988; Andrews et al., 1994). In the present study, we
investigated whether pretreatment of cancer patients with
para-chlorophenyLalanine (PCPA), an inhibitor of serotonin
synthesis, prevents cisplatin-induced emesis and serotonin
release. The urinary excretion of 5-hydroxyindoleatic acid
(5-HIAA), a marker ofgastrointestinal serotonin rekase, and
the development of nausea and vomiting after chemotherapy
with cisplatin were evaluated in cancer patients pretreated
with PCPA.
Ptts and inthod
Ten adult, chemotherapy-naive inpatients with cancer (seven
head and neck and three genitourinary tumours) were
studied. Written informed consent was obtained from all
patients. The study was evaluated and accepted by the Insti-
tutional Review Board at the Luis Razetti Oncology Hospital
of the city of Caracas.
Chemotherapy
All patients received a 60 min intravenous infusion of cis-
platin (70-100mgm-2; mean ± s.e.m. = 93± 3 mgm2)
either alone or associated with mikily emetogenic drugs such
as 5-fluorouracil or etoposide.
PCPA treatment
One subject (male) received 1 g twice daily for 2 days and 1 g
prior to cisplatin. Two patients (one male and one female)
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received 2 g twice daily for 2 days. Four subjects (2M/2F)
received 2 g three times daily for 2 days and three patients
(2M/IF) received 2g three times daily for 3 days. The last
dose of PCPA (1 g in one subject and 2 g in nine subjects)
was given on the morning of the day ofchemotherapy, 1-2 h
before initiating the infusion of cisplatin.
Antiemetic andantinusea activity ofPCPA
Vomiting was directly monitored by the investigators during
the first 8 h following cisplatin administation. The number
of emetic epiodes and the intensity of each emetic episod
(number of retches and vomits per episode) were registered.
Subsequently, and for the next 16 h, the emetic episodes were
recorded by the patient on a dairy. Delayed emesis was not
evaluated.
Antiemetic rescue treatment was initered if patients
experienced three episodes of emesis in any 1 h period.
Ondansetron (8 mgi.v.) was used as rescue antiemetic. The
administration of rescue antiemetic was considered to
indicate insufficient efficacy of the PCPA treatment. The
intensity of nausea was evaluated by means of a 100mm
visual analogue scale. Nausea scores were measured the day
before the chemotherapy, hourly for the first 8 h after cis-
platin and at 12 and 24 h after isplatin administration.
Uriay excretion of5-HIAA
Foods known to have a high serotonin content, as well as
alcohol-containing beverages, were discontinued from 2 days
before initiating the urine colection until the end of the
study. Twenty-four hour urine collections (spontaneous 5-
HLAA excretion) were obtaied the day prior to initiation of
treatment with PCPA (baselne levels), during treatment with
PCPA and for 2 days after termination of the PCPA treat-
ment (Figure 1). During the day of the chemotherapy, urine
samples were colleted at 2 h intervals for a period of 10 h,
starting 2 h before the administration of cisplatin. Subse-
quently, a 14 h urine sample was obtained to complete the
24 h collction period for the day of chemotherapy. 5-HIAA
was determined by high-pressure liquid chromatography with
electrochenical detection, as previously described (Cubeddu
et al., 1990). The sensitivity of the assay was sufficient to
detect 50pg of 5-HIAA.
Stistical anaysis
Data are presented as mean values ± s.e.m. Analysis of
variance (ANOVA) and Duncan's multiple range test wereSwd.WUinsa.L a
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employed to compare differences between groups. A paired
t-test was used to make a one-time comparison when baseline
and treatment values were obtained in the same subject.
Repeated measures ANOVA was used to evaluate multiple
time points in the same subject.
Res
PCPA reduced significantly the spontaneous 24 h urinary
excretion of 5-HIAA. Greater decreases in urinary 5-HIAA
were observed with higher doses and longer treatments
(Figure 1). Cisplatin is known to increase the urinary excre-
tion of 5-HIAA (Cubeddu et al., 1990, 1992) (Figure 2a and
b). Pretreatment with 6 g daily of PCPA inhibited cisplatin-
induced increases in urinary 5-HIAA; 3 days' treatment with
PCPA was more effective than 2 days' treatment. In fact, the
amount of 5-HIAA released by cisplatin averaged 0.13 mg
after 3 days and 1.44 mg after 2 days of treatment with
PCPA. With lower doses of PCPA, cisplatin released
4.1 ± 0.4mg of 5-HLAA in 8 h, an amount similar to that
observed previously in patients treated with similar high
doses of cisplatin (3.8 ± 0.4 mg of 5-HIAA in 8 h) (Cubeddu
et al., 1990, Cubeddu and Hoffmann, 1994).
The emetic response to cisplatin-based chemotherapy is
shown in Table I. After either 2 or 3 days of treatment with
6 g daily of PCPA there was a marked reduction in the
number and the intensity of the emetic episodes produced by
cisplatin. No patient required antiemetic rescue medication in
the 6 g daily dose group, whereas all three subjects on the
lower PCPA dose schedule required rescue antiemetics. A
longer latency time to emesis was observed with 3 than with
2 days of treatment. Of the seven patients who rived 6 g
of PCPA daily, four subjects did not vomit (complete re-
sponse) and the other three experienced mild emesis. The
results obtained with 6g of PCPA daily were favourable
when compared with the lower dose group. Despite the small
number of patients, the percentage of patients requiring
rescue antiemetics, the number and intensity of the emetic
episodes and the requirements of rescue antiemetics in the
high-dose PCPA were similar to those previously reported by
us for ondansetron, and were superior to those reported for
placebo-treated patients (taken from Cubeddu et al.,
1990).
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Fe 1 Effect of PCPA on the spontaneous 24 h urmnary
excretio of 5-HLAA in cancer patents. Shown is the spon-
taneous 24 h urinary excretion of 5-HIAA (mg) before (first bar),
during (middle striped bars) and after (last two bars) PCPA
treatment. Pretreatment histograms cover the 24 h perod before
PCPA ministration. Three PCPA treatment scheduls were
employed: 4 g for 2 days, 6g for 2 days and 6g for 3 days.
The urinary excretion on the chemotherapy day is not shown (see
Figure 2). Shown are mean values ± s.ezn. Sigificantly different
from baseln values at *P<0.05 and **P<0.01.
The antiausea efficacy of PCPA is shown in Figure 3.
Nausea scores increased at 2 h after initiation of cisplatin
infusion, peaked at 3 h and rmained elevated for the 24 h
obration period. Smaller nausea scores (better control of
nausea) wme obtained with 6 than with 4g daily of PCPA.
Further, better control of nausea was obtained with 3 than
with 2 days oftreatment with PCPA (6 g daily). Interestingly,
no differences were observed in the latency ofonset of nausea
between PCPA treatment groups despite the fact that in-
creased latency to emesis was observed after high-dose
PCPA.
No serious adverse events were observed in the study.
Headache was reported by 4/10 subjects, constipation by 3/10
subjects and sadness, lack ofenergy and desire to stay in bed
were present in three subjects.
PCPA is a well-known serotonin synthesis inhibitor, which
has been previously inid to human subjects and
patients (Cremata and Koe, 1966; Koe and Weissman, 1966;
Enge}man et al., 1967). In healthy subjects, daily PCPA doses
of 2g for 12 days or 3 g for 5 days produced no serious
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Flge 2 Effects of PCPA on cisplatin-induced incraes in the
urinary excretion of 5-HIAA in cancer patients. Cisplatin
infusion lasted l h and was started at time zero. Urnes were
collected for 10 h at 2 h intervals. Collction started 2h before
the initiation of the cisplatin infusion. The pre-cisplatin sample
(-2 to 0) was consider as the basehne sample. Three PCPA
treatment schedules were employed: <4 g for 2 days, 6 g for 2
days and 6g for 3 days. The last dose of PCPA was given 1-2 h
before cisplatin. (a) The effects of PCPA on the time course of
the ineases in urinary 5-HIAA (mg) following csplatin. Results
are shown as the milligrams of5-HIAA that were excreted above
baselielevels in 2 h peiods. (b) The cumulative urinary excre-
tion of 5-HLAA in milligrams throughout the 8 h period that
follows the initiation of cisplatin infusion. Shown are means +
s.e.M. Significantly different from the low-dose PCPA group at
*P<0.05 and **P<0.01.
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Table I Antiemetic efficacy of PCPA in cancer patients receiving cisplatin-based
chemotherapy
PCPA treatment schedules
.<44gda}y-r 6gda)y-' 6gday-1 Placebo Ondanrtron
(n =3) (n =4) (n =3) (n =4) (n =14)
Number of days 2 2 3 - -
of treatment
Rescue antiemetic 100 0 0 86 0
(per cent of patients)
None or one 03 34 3/3 0114 6/14
episode of vomiting
Number of emetic 4.7 1.5 0.3 5.2 1.5
episodes/24 h
Number of vomits 2.5 1.4 1.0 2.4 1.2
emetic episodea
Time to the onset 1.9 1.9 6.9 2.8 11.6
of emesis (h)'
Data obtained for the first 24 h after cisplatin infusion. Data from
ondansetron-treated patients were taken from Cubeddu et al. (1990). The
patients received a single 8 mg i.v. dose of ondansetron. aIncludes only
vomiting not dry retching.
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Frwe 3 Effects of PCPA on nausea scores in cancer patients
receiving treatment with cisplatin. One hundred millimetres visual
analogue sakes (VAS in mm) were employed to assess the inten-
sity of nausea induced by cisplatin. Assessments were made 24 h
before, hourly for 8 h and at 12 and 24 h after isplatin. The
infusion of cisplatin started at time zero and lasted for I h. The
1 h nausea asssment was made just after completion of the
isplatin infusion. Shown are means ± s.e.m. *Significantly
different from the low dose group at P<0.05.
adverse events. Tiredness, lightheadedness, diinss, loss of
bala, headache and nausea were the most commonly re-
ported side-effects. These side-effects disappeared 1-2 days
after discontinuing PCPA. Further, PCPA produced no alter-
ations in the haematological or chemical laboratory profile of
the subjects (Cremata and Koe, 1966). In patients harbour-
ing carcinoid tumours, PCPA has been administered for
prolonged periods of time (from 7 days to 5 months) at doses
as high as 4 g daily and up to 28 g in 7 days and 300 g in 5
months (Engelman et al., 1967). These authors reported no
serious adverse events, and fatigue, diziness and headache
were the most common side-effects observed. The goal of the
present work was to achieve important serotonin depletion in
a short time period, in order to avoid any delay in admini-
stering the indicated chemotherapy treatment to the cancer
patients. For better monitoring, as well as for safety reasons,
only inpatients were studied, a maxiimum of 3 days' treat-
ment was given, the first three patients received the lowest
doses of PCPA and all patients were closely monitored by an
investigator during the period of treatment and for three
additional days following treatment cessation. Similarly to
what has been reported by others (see above), PCPA was
well tolerated and no serious adverse events occurred. The
side-effects observed by us (headaches, constipation and lack
ofenergy) are similar-to those observed by Cremata and Koe
(1966) and by Engelman et al. (1967), and to those observed
with ondansetron, a selective antagonist of 5-HT3 receptors
(Cubeddu et al., 1990, 1994).
The gut is estimated to contain more than 80% of the
serotonin in the body, and, of this, 95% is located within the
enterochromaffin cells (Resnick and Gray, 1961). When the
gastrointestinal tract is totally or partially resected, the
urinary excretion of 5-HIAA is abolished or reduced respec-
tively (Bertaccini, 1960; Bertaccini and Chieppa, 1960). These
findings as well as other evidence indicate that urinary excre-
tion of 5-HIAA provides a convenient index of serotonin
release from the gastrointestinal tract (Cubeddu, 1992).
Cisplatin-induced serotonin release is manifested in cancer
patients by increases in urinary 5-HIAA (Cubeddu et al.,
1990, 1992; Cubeddu and Hoffmann, 1993). In this work, we
demonstrated in human cancer patients that treatment with a
serotonin synthesis inhibitor decreases the spontaneous
urinary excretion of 5-HIAA and, in addition, reduces the
cisplatin-induced increases in urinary 5-HIAA. These effects
of PCPA on 5-HIAA excretion are most likely the conse-
quence of depletion of gastrointestinal serotonin. Associated
with the reduction in urinary 5-HIAA, PCPA antagonised
cisplatin-induced nausea and emesis, and the antiemetic
activity of PCPA was similar to or even better than that
previously reported by us with ondansetron, a selective
antagonist of 5-HT3 receptors (Cubeddu et al., 1990). Conse-
quently, although based on a small number of patients, our
results provide further support for the view that the emetic
action of isplatin is mediated by the release of gastrointes-
tinal serotonin induced by the chemotherapeutic drug. When
the gastrointestinal serotonin content is markedly reduced
(diminished spontaneous 5-HLAA excretion), cisplatin can
only elicit a very small release of serotonin, associated with
little or no nausea and vomiting (present study).
PCPA is known to deplete neuronal stores of serotonin
more rapidly and effectively than the serotonin located in
endocrine cells (enterochromaffin cells) (Weber, 1970). For
example, chronic PCPA treatment in ferrets reduced
serotonin levels in the dorsal brain stem and the hypo-
thalamus by more than 90%, whereas the levels in duodenum
and ileum were reduced by 25% and 55% respectively (And-
rews, 1994). Assuming that in humans PCPA retains its
greater seectivity for neuronal than for enterochromaffin
serotonin, it is expected that a 50% reduction in urinary
5-HLAA should be accompanied by a marked depletion of
neuronal serotonin. Consequently, the failure of low-dose
PCPA to inhibit the emetic response to cisplatin despite
reducing urinary 5-HIAA by 50% supports the view that it is
enterochromaffin and not neuronal serotonin which mediates
the emetic response to cisplatin.
In conclusion, administration of the inhibitor of serotonin
synthesis, PCPA, to cancer patients reduced the spontaneousSerbxn ndchm- ihmd~ py4 -
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urinary excretion of 5-HIAA and inhibited the increase in
urinary 5-HIAA and the nausea and vomiting induced by
cisplatin. Nausea and vomiting were antagonised when the
amount of serotonin released by cisplatin was considerably
reduced. These findings strongly support the view that
serotonin released from gastrointestinal enterochromaffin
cells mediates the emetic response to cisplatin in human
patients. In addition, we suggest that the amount of
serotonin released is a main determinant of the severity of
the emetic response to cisplatin. However, it should be
stressed that serotonin release is probably one of the many
effects of chemotherapy that are involved in the tnrggering of
emesis.
Acuow Its
The authors would like to thank Drs Luis E Palacios, Jose Ricardo
Perez and Mireya Rodriguez, the nurses of the Chemotherapy Unit
and the medical and paramedical personnel of the Oncology Hos-
pital 'Luis Razeti' of the City of Caracas.
This study was supported by the Consejo de Desarrollo Cientifico
y Humanistico de la UCV, Grants nos. 07.10.2382-93 and
06.10.2441-93.
References
ANDREWS PRL. (1994). 5-HT3 receptors antagonists and antiemesis
In 5-Hydroxytryptamnes-3 Receptors Antagonmis, King F, Jones B
and Sanger G (eds). pp. 255-317. CRC Press Boca Raton, FL.
BARNES NM, BARRY JM, COSTALL B. NAYLOR RJ AND TATTER-
SALL FD. (1988). Antagonism by parachlorophenylalanine of
cisplatin-induced emesis. Br. J. Pharmacol., 92, 649.
BERTACCINI G. (1960). Tissue 5-hydroxytryptamine and urinary
5-hydroxyindoleacetic acid after partial or total removal of the
gastro-intestinal tract in the rat. J. Physiol., 153, 239-249.
BERTACCINI G AND CHIEPPA S. (1960). Urinary excretion of 5-
hydroxyindoeacetic acid after removal of the large intestine in
man. Lancet, Z78, 881.
COSTALL B, DOMENEY AM, NAYLOR RJ, TATTERSALI FD AND
TYERS MB. (1986). 5-Hydroxytryptamine M-receptor antagonism
to prevent cisplatinum-induced emesis. Neuropharmacology, 25,
959.
CREMATA VY AND KOE K. (1966). Clinical-pharmacological evalu-
ation of p-chlorophenylalanine: a new serotonin-depleting agent.
Clin. Pharmacol. Ther., 7, 768-776.
CUBEDDU LX. (1992). The role of serotonin in chemotherapy-
induced emesis in cancer patients. In Antiemetic Therapy: Current
Status and Future Prospects, Diaz Rubio E and Martin M (eds)
pp. 40-55. Creaciones Elba: Madrid.
CUBEDDU LX AND HOFFMANN IS. (1993). Participation of sero-
tonin on early and delayed emesis induced by initial and subse-
quent cycles of cisplatinum-based chemotherapy: effects of
dexamethasone and metoclopramide. J. Clia. Pharmacol., 33,
691-697.
CUBEDDU LX AND HOFFMANN IS. (1994). Mechanisms of the
emetic response to chemotherapy and of the antiemetic action of
5-HT3-receptor antagonists: clinical studies. In Serotonin: From
Cell Biolog) to Pharmacology and Therapeutics, Vanhoutte PM,
Sadena PR, Paoletti R, Brunello N and Jackson AS (eds)
pp. 171-178. Kluwer Academic: London.
CUBEDDU LX HOFFMANN IS. FUENMAYOR NT AND FINN AL.
(1990). Efficacy of ondansetron (GR38032F) and the role of
serotonin in cisplatin-induced nausea and vomiting. N. Engl. J.
Med., 322, 810-816.
CUBEDDU LX, HOFFMANN IS, FUENMAYOR NT AND MALAVE JJ.
(1992). Changes in serotonin metabolism in cancer patient: its
relationship to nausea and vomiting induced by chemotherapeutic
drugs. Br. J. Cancer, 66, 198-203.
ENGELMAN K. LOVENBERG W AND SJODRSMA A. (1967). Inhibi-
tion of serotonin synthesis by parachlorophenylalanine in patients
with the carcinoid syndrome. N. Engl. J. Med., 277,
1103-1108.
GRALLA RJ. (1983). Metoclopramide: a review of antiemetic trials.
Drugs, 25 (Suppl. 1). 63-73.
KOE KB AND WEISSMAN A. (1966). p-chlorophenylalanine: a
specific depletor of brain serotonin. J. Pharmacol. Exp. Ther.,
154, 499-516.
MARTIN M. (1992). Undesirable effects associated with chemo-
therapy-induced emesis. In Antiemetic Therapy: Current Status
and Future Prospects, Diaz Rubio E and Martin M (eds)
pp. 57-68. Ediciones Elba: Madrid.
MINER WD AND SANGER GJ. (1986). Inhibition of cisplatin-induced
vomiting by selective 5-hydroxytriptamine M-receptor an-
tagonism. Br. J. Pharmacol., 88, 497-499.
RESNICK BH AND GRAY SJ. (1961). Distribution of serotonin (5-
hydroxytryptamine) in the human gastrointestinal tract. Gastro-
enterology, 41, 119-121.
WEBER LJ. (1970). p-Chlorophenylalanine-induced depletion of
gastrointestinal 5-hydroxytryptamine. Biochem. Pharmacol., 19,
2169-2172.